Drug information provided by: Merative, Micromedex®
Dabrafenib is used alone or in combination with trametinib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery. It is also used together with trametinib to help prevent melanoma from coming back after surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations. Dabrafenib is also used together with trametinib to treat non-small cell lung cancer (NSCLC) that has spread and anaplastic thyroid cancer (ATC) that has spread and has no satisfactory treatment options. It is only used if the NSCLC cells and ATC cells have the BRAF V600E mutation. Dabrafenib is also used in combination with trametinib to treat solid tumors that have spread, that cannot be removed by surgery, or that have gotten worse (progressed) and has no satisfactory treatment options. It is only used if the solid tumors have the BRAF V600E mutations. Dabrafenib is also used in combination with trametinib to treat low-grade glioma (LGG) in patients who require other treatments. It is only used if the brain tumor has the BRAF V600E mutations. Your doctor will use a special test to look for these mutations. Dabrafenib belongs to the group of medicines, called antineoplastics (cancer medicines).
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go twice as far to advance cancer research and care!